肝細胞がん(Hepatocellular Carcinoma):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Hepatocellular Carcinoma - Pipeline Review, H2 2014
◆商品コード:GMDHC5676IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月18日
◆ページ数:669
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における肝細胞がん(Hepatocellular Carcinoma)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・肝細胞がん(Hepatocellular Carcinoma)の概要
・肝細胞がん(Hepatocellular Carcinoma)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・肝細胞がん(Hepatocellular Carcinoma)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・肝細胞がん(Hepatocellular Carcinoma)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・肝細胞がん(Hepatocellular Carcinoma)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Hepatocellular Carcinoma – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Hepatocellular Carcinoma – Pipeline Review, H2 2014’, provides an overview of the Hepatocellular Carcinoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hepatocellular Carcinoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hepatocellular Carcinoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hepatocellular Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hepatocellular Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
Introduction 7
Hepatocellular Carcinoma Overview 8
Therapeutics Development 9
Hepatocellular Carcinoma – Therapeutics under Development by Companies 11
Hepatocellular Carcinoma – Therapeutics under Investigation by Universities/Institutes 20
Hepatocellular Carcinoma – Pipeline Products Glance 22
Hepatocellular Carcinoma – Products under Development by Companies 25
Hepatocellular Carcinoma – Products under Investigation by Universities/Institutes 36
Hepatocellular Carcinoma – Companies Involved in Therapeutics Development 38
Hepatocellular Carcinoma – Therapeutics Assessment 143
Drug Profiles 162
Hepatocellular Carcinoma – Recent Pipeline Updates 451
Hepatocellular Carcinoma – Dormant Projects 635
Hepatocellular Carcinoma – Discontinued Products 641
Hepatocellular Carcinoma – Product Development Milestones 643
Appendix 650

[List of Tables]
Number of Products under Development for Hepatocellular Carcinoma, H2 2014 27
Number of Products under Development for Hepatocellular Carcinoma - Comparative Analysis, H2 2014 28
Number of Products under Development by Companies, H2 2014 30
Number of Products under Development by Companies, H2 2014 (Contd..1) 31
Number of Products under Development by Companies, H2 2014 (Contd..2) 32
Number of Products under Development by Companies, H2 2014 (Contd..3) 33
Number of Products under Development by Companies, H2 2014 (Contd..4) 34
Number of Products under Development by Companies, H2 2014 (Contd..5) 35
Number of Products under Development by Companies, H2 2014 (Contd..6) 36
Number of Products under Development by Companies, H2 2014 (Contd..7) 37
Number of Products under Investigation by Universities/Institutes, H2 2014 39
Comparative Analysis by Late Stage Development, H2 2014 40
Comparative Analysis by Clinical Stage Development, H2 2014 41
Comparative Analysis by Early Stage Development, H2 2014 42
Products under Development by Companies, H2 2014 43
Products under Development by Companies, H2 2014 (Contd..1) 44
Products under Development by Companies, H2 2014 (Contd..2) 45
Products under Development by Companies, H2 2014 (Contd..3) 46
Products under Development by Companies, H2 2014 (Contd..4) 47
Products under Development by Companies, H2 2014 (Contd..5) 48
Products under Development by Companies, H2 2014 (Contd..6) 49
Products under Development by Companies, H2 2014 (Contd..7) 50
Products under Development by Companies, H2 2014 (Contd..8) 51
Products under Development by Companies, H2 2014 (Contd..9) 52
Products under Development by Companies, H2 2014 (Contd..10) 53
Products under Investigation by Universities/Institutes, H2 2014 54
Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 55
Hepatocellular Carcinoma - Pipeline by 4SC AG, H2 2014 56
Hepatocellular Carcinoma - Pipeline by AbbVie Inc., H2 2014 57
Hepatocellular Carcinoma - Pipeline by Acceleron Pharma, Inc., H2 2014 58
Hepatocellular Carcinoma - Pipeline by ACROVIS biostructures GmbH, H2 2014 59
Hepatocellular Carcinoma - Pipeline by Alfact Innovation, H2 2014 60
Hepatocellular Carcinoma - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2014 61
Hepatocellular Carcinoma - Pipeline by Amgen Inc., H2 2014 62
Hepatocellular Carcinoma - Pipeline by AndroScience Corporation, H2 2014 63
Hepatocellular Carcinoma - Pipeline by ArQule, Inc., H2 2014 64
Hepatocellular Carcinoma - Pipeline by Arrowhead Research Corporation, H2 2014 65
Hepatocellular Carcinoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2014 66
Hepatocellular Carcinoma - Pipeline by AstraZeneca PLC, H2 2014 67
Hepatocellular Carcinoma - Pipeline by Avidin Ltd, H2 2014 68
Hepatocellular Carcinoma - Pipeline by Bayer AG, H2 2014 69
Hepatocellular Carcinoma - Pipeline by Bio-Cancer Treatment International Limited, H2 2014 70
Hepatocellular Carcinoma - Pipeline by Blueprint Medicines, H2 2014 71
Hepatocellular Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2014 72
Hepatocellular Carcinoma - Pipeline by Boston Biomedical, Inc., H2 2014 73
Hepatocellular Carcinoma - Pipeline by Can-Fite BioPharma Ltd., H2 2014 74
Hepatocellular Carcinoma - Pipeline by CASI Pharmaceuticals Inc., H2 2014 75
Hepatocellular Carcinoma - Pipeline by CCRP Therapeutics GmbH, H2 2014 76
Hepatocellular Carcinoma - Pipeline by Celgene Corporation, H2 2014 77
Hepatocellular Carcinoma - Pipeline by Celsion Corporation, H2 2014 78
Hepatocellular Carcinoma - Pipeline by China Medical System Holdings Limited, H2 2014 79
Hepatocellular Carcinoma - Pipeline by Chroma Therapeutics Ltd., H2 2014 80
Hepatocellular Carcinoma - Pipeline by CrystalGenomics, Inc., H2 2014 81
Hepatocellular Carcinoma - Pipeline by CytRx Corporation, H2 2014 82
Hepatocellular Carcinoma - Pipeline by Delcath Systems, Inc., H2 2014 83
Hepatocellular Carcinoma - Pipeline by Dicerna Pharmaceuticals, Inc., H2 2014 84
Hepatocellular Carcinoma - Pipeline by Digna Biotech, S.L., H2 2014 85
Hepatocellular Carcinoma - Pipeline by Eisai Co., Ltd., H2 2014 86
Hepatocellular Carcinoma - Pipeline by Eli Lilly and Company, H2 2014 87
Hepatocellular Carcinoma - Pipeline by Endocyte, Inc., H2 2014 88
Hepatocellular Carcinoma - Pipeline by Exelixis, Inc., H2 2014 89
Hepatocellular Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 90
Hepatocellular Carcinoma - Pipeline by Gamida Cell Ltd., H2 2014 91
Hepatocellular Carcinoma - Pipeline by Genelux Corporation, H2 2014 92
Hepatocellular Carcinoma - Pipeline by Genoscience Pharma, H2 2014 93
Hepatocellular Carcinoma - Pipeline by GenSpera, Inc., H2 2014 94
Hepatocellular Carcinoma - Pipeline by GlaxoSmithKline plc, H2 2014 95
Hepatocellular Carcinoma - Pipeline by Green Cross Cell Corporation, H2 2014 96
Hepatocellular Carcinoma - Pipeline by Immune Network, Ltd., H2 2014 97
Hepatocellular Carcinoma - Pipeline by Immunicum AB, H2 2014 98
Hepatocellular Carcinoma - Pipeline by Immunomedics, Inc., H2 2014 99
Hepatocellular Carcinoma - Pipeline by Immunovative Therapies, Ltd., H2 2014 100
Hepatocellular Carcinoma - Pipeline by Immuron Limited, H2 2014 101
Hepatocellular Carcinoma - Pipeline by In Cell Art, H2 2014 102
Hepatocellular Carcinoma - Pipeline by Incuron, LLC, H2 2014 103
Hepatocellular Carcinoma - Pipeline by Intezyne, Inc, H2 2014 104
Hepatocellular Carcinoma - Pipeline by KAEL-GemVax Co., Ltd., H2 2014 105
Hepatocellular Carcinoma - Pipeline by KAHR medical Ltd., H2 2014 106
Hepatocellular Carcinoma - Pipeline by Kowa Company, Ltd., H2 2014 107
Hepatocellular Carcinoma - Pipeline by La Jolla Pharmaceutical Company, H2 2014 108
Hepatocellular Carcinoma - Pipeline by Ligand Pharmaceuticals, Inc., H2 2014 109
Hepatocellular Carcinoma - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2014 110
Hepatocellular Carcinoma - Pipeline by MaxCyte, Inc., H2 2014 111
Hepatocellular Carcinoma - Pipeline by Merck KGaA, H2 2014 112
Hepatocellular Carcinoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 113
Hepatocellular Carcinoma - Pipeline by MolMed S.p.A., H2 2014 114
Hepatocellular Carcinoma - Pipeline by MultiCell Technologies, Inc., H2 2014 115
Hepatocellular Carcinoma - Pipeline by NeoStem, Inc., H2 2014 116
Hepatocellular Carcinoma - Pipeline by Nerviano Medical Sciences, H2 2014 117
Hepatocellular Carcinoma - Pipeline by Novartis AG, H2 2014 118
Hepatocellular Carcinoma - Pipeline by Nymox Pharmaceutical Corporation, H2 2014 119
Hepatocellular Carcinoma - Pipeline by Omeros Corporation, H2 2014 120
Hepatocellular Carcinoma - Pipeline by Oncolys BioPharma Inc., H2 2014 121
Hepatocellular Carcinoma - Pipeline by OncoTherapy Science, Inc., H2 2014 122
Hepatocellular Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 123
Hepatocellular Carcinoma - Pipeline by Onxeo SA, H2 2014 124
Hepatocellular Carcinoma - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 125
Hepatocellular Carcinoma - Pipeline by Panacea Pharmaceuticals, Inc., H2 2014 126
Hepatocellular Carcinoma - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2014 127
Hepatocellular Carcinoma - Pipeline by Pfizer Inc., H2 2014 128
Hepatocellular Carcinoma - Pipeline by PharmaEssentia Corporation, H2 2014 129
Hepatocellular Carcinoma - Pipeline by PhaseRx, Inc., H2 2014 130
Hepatocellular Carcinoma - Pipeline by Polaris Group, H2 2014 131
Hepatocellular Carcinoma - Pipeline by Priaxon AG, H2 2014 132
Hepatocellular Carcinoma - Pipeline by Progen Pharmaceuticals Limited, H2 2014 133
Hepatocellular Carcinoma - Pipeline by Provecs Medical GmbH, H2 2014 134
Hepatocellular Carcinoma - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2014 135
Hepatocellular Carcinoma - Pipeline by Quantum Pharmaceuticals, H2 2014 136
Hepatocellular Carcinoma - Pipeline by Raptor Pharmaceuticals Corp., H2 2014 137
Hepatocellular Carcinoma - Pipeline by Regulus Therapeutics Inc., H2 2014 138
Hepatocellular Carcinoma - Pipeline by Rigontec GmbH, H2 2014 139
Hepatocellular Carcinoma - Pipeline by Santaris Pharma A/S, H2 2014 140
Hepatocellular Carcinoma - Pipeline by Sevion Therapeutics, Inc., H2 2014 141
Hepatocellular Carcinoma - Pipeline by Shanghai Sunway Biotech Co., Ltd, H2 2014 142
Hepatocellular Carcinoma - Pipeline by Shenogen Pharma Group Ltd., H2 2014 143
Hepatocellular Carcinoma - Pipeline by Silence Therapeutics plc, H2 2014 144
Hepatocellular Carcinoma - Pipeline by SillaJen Co. Ltd., H2 2014 145
Hepatocellular Carcinoma - Pipeline by Simcere Pharmaceutical Group, H2 2014 146
Hepatocellular Carcinoma - Pipeline by Solasia Pharma K.K., H2 2014 147
Hepatocellular Carcinoma - Pipeline by Synta Pharmaceuticals Corp., H2 2014 148
Hepatocellular Carcinoma - Pipeline by Taiwan Liposome Company, Ltd., H2 2014 149
Hepatocellular Carcinoma - Pipeline by Tekmira Pharmaceuticals Corp., H2 2014 150
Hepatocellular Carcinoma - Pipeline by Therametrics holding AG, H2 2014 151
Hepatocellular Carcinoma - Pipeline by Therapure Biopharma Inc., H2 2014 152
Hepatocellular Carcinoma - Pipeline by THERAVECTYS SA, H2 2014 153
Hepatocellular Carcinoma - Pipeline by Threshold Pharmaceuticals, Inc., H2 2014 154
Hepatocellular Carcinoma - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H2 2014 155
Hepatocellular Carcinoma - Pipeline by TRACON Pharmaceuticals, Inc., H2 2014 156
Hepatocellular Carcinoma - Pipeline by Vaxon Biotech, H2 2014 157
Hepatocellular Carcinoma - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2014 158
Hepatocellular Carcinoma - Pipeline by Vicus Therapeutics, LLC, H2 2014 159
Hepatocellular Carcinoma - Pipeline by Virttu Biologics Limited, H2 2014 160
Assessment by Monotherapy Products, H2 2014 161
Assessment by Combination Products, H2 2014 162
Number of Products by Stage and Target, H2 2014 164
Number of Products by Stage and Mechanism of Action, H2 2014 171
Number of Products by Stage and Route of Administration, H2 2014 177
Number of Products by Stage and Molecule Type, H2 2014 179
Hepatocellular Carcinoma Therapeutics - Recent Pipeline Updates, H2 2014 469
Hepatocellular Carcinoma - Dormant Projects, H2 2014 653
Hepatocellular Carcinoma - Dormant Projects (Contd..1), H2 2014 654
Hepatocellular Carcinoma - Dormant Projects (Contd..2), H2 2014 655
Hepatocellular Carcinoma - Dormant Projects (Contd..3), H2 2014 656
Hepatocellular Carcinoma - Dormant Projects (Contd..4), H2 2014 657
Hepatocellular Carcinoma - Dormant Projects (Contd..5), H2 2014 658
Hepatocellular Carcinoma - Discontinued Products, H2 2014 659
Hepatocellular Carcinoma - Discontinued Products (Contd..1), H2 2014 660

[List of Figures]
Number of Products under Development for Hepatocellular Carcinoma, H2 2014 27
Number of Products under Development for Hepatocellular Carcinoma - Comparative Analysis, H2 2014 28
Number of Products under Development by Companies, H2 2014 29
Number of Products under Investigation by Universities/Institutes, H2 2014 38
Comparative Analysis by Clinical Stage Development, H2 2014 41
Comparative Analysis by Early Stage Products, H2 2014 42
Assessment by Monotherapy Products, H2 2014 161
Assessment by Combination Products, H2 2014 162
Number of Products by Top 10 Targets, H2 2014 163
Number of Products by Stage and Top 10 Targets, H2 2014 163
Number of Products by Top 10 Mechanism of Actions, H2 2014 170
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 170
Number of Products by Top 10 Routes of Administration, H2 2014 176
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 177
Number of Products by Top 10 Molecule Types, H2 2014 178
Number of Products by Stage and Top 10 Molecule Types, H2 2014 179

【掲載企業】

4SC AG
AbbVie Inc.
Acceleron Pharma, Inc.
ACROVIS biostructures GmbH
Alfact Innovation
Alnylam Pharmaceuticals, Inc.
Amgen Inc.
AndroScience Corporation
ArQule, Inc.
Arrowhead Research Corporation
Astex Pharmaceuticals, Inc.
AstraZeneca PLC
Avidin Ltd
Bayer AG
Bio-Cancer Treatment International Limited
Blueprint Medicines
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Can-Fite BioPharma Ltd.
CASI Pharmaceuticals Inc.
CCRP Therapeutics GmbH
Celgene Corporation
Celsion Corporation
China Medical System Holdings Limited
Chroma Therapeutics Ltd.
CrystalGenomics, Inc.
CytRx Corporation
Delcath Systems, Inc.
Dicerna Pharmaceuticals, Inc.
Digna Biotech, S.L.
Eisai Co., Ltd.
Eli Lilly and Company
Endocyte, Inc.
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
Gamida Cell Ltd.
Genelux Corporation
Genoscience Pharma
GenSpera, Inc.
GlaxoSmithKline plc
Green Cross Cell Corporation
Immune Network, Ltd.
Immunicum AB
Immunomedics, Inc.
Immunovative Therapies, Ltd.
Immuron Limited
In Cell Art
Incuron, LLC
Intezyne, Inc
KAEL-GemVax Co., Ltd.
KAHR medical Ltd.
Kowa Company, Ltd.
La Jolla Pharmaceutical Company
Ligand Pharmaceuticals, Inc.
Lixte Biotechnology Holdings, Inc.
MaxCyte, Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
MolMed S.p.A.
MultiCell Technologies, Inc.
NeoStem, Inc.
Nerviano Medical Sciences
Novartis AG
Nymox Pharmaceutical Corporation
Omeros Corporation
Oncolys BioPharma Inc.
OncoTherapy Science, Inc.
Ono Pharmaceutical Co., Ltd.
Onxeo SA
Otsuka Holdings Co., Ltd.
Panacea Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc.
Pfizer Inc.
PharmaEssentia Corporation
PhaseRx, Inc.
Polaris Group
Priaxon AG
Progen Pharmaceuticals Limited
Provecs Medical GmbH
Provectus Biopharmaceuticals, Inc.
Quantum Pharmaceuticals
Raptor Pharmaceuticals Corp.
Regulus Therapeutics Inc.
Rigontec GmbH
Santaris Pharma A/S
Sevion Therapeutics, Inc.
Shanghai Sunway Biotech Co., Ltd
Shenogen Pharma Group Ltd.
Silence Therapeutics plc
SillaJen Co. Ltd.
Simcere Pharmaceutical Group
Solasia Pharma K.K.
Synta Pharmaceuticals Corp.
Taiwan Liposome Company, Ltd.
Tekmira Pharmaceuticals Corp.
Therametrics holding AG
Therapure Biopharma Inc.
THERAVECTYS SA
Threshold Pharmaceuticals, Inc.
Toko Pharmaceutical Industries Co., Ltd.
TRACON Pharmaceuticals, Inc.
Vaxon Biotech
Vertex Pharmaceuticals Incorporated
Vicus Therapeutics, LLC
Virttu Biologics Limited

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[肝細胞がん(Hepatocellular Carcinoma):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆